Quviviq is a dual orexin receptor antagonist.
The approval was based on data from an ongoing phase 3 trial evaluating the safety and tolerability of brexpiprazole as maintenance treatment of 194 patients aged 13 to 17 years with schizophrenia.
Study authors analyzed data from 10,541 hospitalized patients with active COVID-19 disease to evaluate the relationship between the use of statins and COVID-19 outcomes.
Azstarys consists of serdexmethylphenidate, a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate.
The FDA has updated the fact sheet for the Janssen COVID-19 vaccine to include information related to an increased risk of Guillain-Barré syndrome.
An updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant is also in the works.
The treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
The FDA is concerned that obtaining falsely low test results may lead to inappropriate follow-up assessments, which may result in patient harm.
Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
Lecanemab (BAN2401) is an investigational anti-amyloid beta protofibril antibody
for the treatment of Alzheimer disease.
